What is the difference between Lanreotide and Octreotide?

Lanreotide is classified as: Long-acting synthetic somatostatin analog (cyclic octapeptide). Octreotide is classified as: Synthetic somatostatin analog (octapeptide); inhibitor of growth hormone and gastroenteropancreatic hormone secretion. Lanreotide is approved for one or more medical uses in at least one major jurisdiction. Octreotide is approved for one or more medical uses in at least one major jurisdiction.

Is Lanreotide or Octreotide approved?

Lanreotide is approved for one or more medical uses in at least one major jurisdiction. Octreotide is approved for one or more medical uses in at least one major jurisdiction. Regulatory status by region is set out in the table above.

How much clinical trial evidence is tracked for Lanreotide and Octreotide?

Peptide Science Daily tracks 117 registered clinical trials for Lanreotide (evidence grade A) and 325 for Octreotide (evidence grade A).

Compound comparison

Lanreotide vs Octreotide

This page sets Lanreotide and Octreotide side by side using the data recorded on Peptide Science Daily: drug class, mechanism of action, regulatory status by region, the evidence grade assigned here, and the number of clinical trials tracked. It is a neutral, factual comparison and does not rank either compound or recommend one over the other.

Side-by-side comparison

Class: Lanreotide
Long-acting synthetic somatostatin analog (cyclic octapeptide)
Octreotide
Synthetic somatostatin analog (octapeptide); inhibitor of growth hormone and gastroenteropancreatic hormone secretion
Mechanism: Lanreotide
Lanreotide is a long-acting copy of somatostatin that damps down hormone secretion and slows the growth of certain tumors.
Octreotide
Octreotide is a lab-made copy of somatostatin, a natural hormone that switches off the release of several other hormones.
United States (FDA): Lanreotide
Approved. Acromegaly (Somatuline Depot, August 2007); gastroenteropancreatic neuroendocrine tumors, to improve progression-free survival (December 2014); carcinoid syndrome (2017).
Octreotide
Approved. Acromegaly, plus symptoms associated with metastatic carcinoid tumors and VIPomas (Sandostatin, 1988); a long-acting depot form (Sandostatin LAR) is also approved.
European Union (EMA): Lanreotide
Authorised and marketed in EU member states (nationally authorised; brand Somatuline Autogel).
Octreotide
Authorised and marketed in EU member states (nationally authorised; brand Sandostatin).
Australia (TGA): Lanreotide
Registered on the ARTG as a prescription medicine (Somatuline Autogel, sponsor Ipsen), since September 2003.
Octreotide
Registered on the ARTG as a prescription medicine (Sandostatin and Sandostatin LAR).
WADA: Lanreotide
Not listed on the WADA Prohibited List; somatostatin analogs are not among the prohibited peptide-hormone classes.
Octreotide
Not listed on the WADA Prohibited List; somatostatin analogs are not among the prohibited peptide-hormone classes.
Evidence grade: Lanreotide
A
Octreotide
A
Tracked clinical trials: Lanreotide
117
Octreotide
325
Full profile: Lanreotide
Lanreotide profile
Octreotide
Octreotide profile

Comparison of Lanreotide and Octreotide by class, mechanism, regulatory status by region, evidence grade, and number of tracked clinical trials.
Attribute	Lanreotide	Octreotide
Class	Long-acting synthetic somatostatin analog (cyclic octapeptide)	Synthetic somatostatin analog (octapeptide); inhibitor of growth hormone and gastroenteropancreatic hormone secretion
Mechanism	Lanreotide is a long-acting copy of somatostatin that damps down hormone secretion and slows the growth of certain tumors.	Octreotide is a lab-made copy of somatostatin, a natural hormone that switches off the release of several other hormones.
United States (FDA)	Approved. Acromegaly (Somatuline Depot, August 2007); gastroenteropancreatic neuroendocrine tumors, to improve progression-free survival (December 2014); carcinoid syndrome (2017).	Approved. Acromegaly, plus symptoms associated with metastatic carcinoid tumors and VIPomas (Sandostatin, 1988); a long-acting depot form (Sandostatin LAR) is also approved.
European Union (EMA)	Authorised and marketed in EU member states (nationally authorised; brand Somatuline Autogel).	Authorised and marketed in EU member states (nationally authorised; brand Sandostatin).
Australia (TGA)	Registered on the ARTG as a prescription medicine (Somatuline Autogel, sponsor Ipsen), since September 2003.	Registered on the ARTG as a prescription medicine (Sandostatin and Sandostatin LAR).
WADA	Not listed on the WADA Prohibited List; somatostatin analogs are not among the prohibited peptide-hormone classes.	Not listed on the WADA Prohibited List; somatostatin analogs are not among the prohibited peptide-hormone classes.
Evidence grade	A	A
Tracked clinical trials	117	325
Full profile	Lanreotide profile	Octreotide profile

Common questions

What is the difference between Lanreotide and Octreotide?: Lanreotide is classified as: Long-acting synthetic somatostatin analog (cyclic octapeptide). Octreotide is classified as: Synthetic somatostatin analog (octapeptide); inhibitor of growth hormone and gastroenteropancreatic hormone secretion. Lanreotide is approved for one or more medical uses in at least one major jurisdiction. Octreotide is approved for one or more medical uses in at least one major jurisdiction.
Is Lanreotide or Octreotide approved?: Lanreotide is approved for one or more medical uses in at least one major jurisdiction. Octreotide is approved for one or more medical uses in at least one major jurisdiction. Regulatory status by region is set out in the table above.
How much clinical trial evidence is tracked for Lanreotide and Octreotide?: Peptide Science Daily tracks 117 registered clinical trials for Lanreotide (evidence grade A) and 325 for Octreotide (evidence grade A).